시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 인간 호흡기 세포융합 바이러스 치료 시장 보고서(2025년)
Human Respiratory Syncytial Virus Treatment Global Market Report 2025
상품코드 : 1751022
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,170,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,918,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,666,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

인간 호흡기 세포융합 바이러스 치료 시장 규모는 향후 몇 년간 강력한 성장이 예상될 예정입니다. 예측 기간의 성장은 단일 클론 항체에 대한 수요 증가, RSV 백신 개발에 대한 투자 증가, 조기 진단에 대한 집중도 증가, 개발도상국의 의료 서비스 접근성 확대, 새로운 치료법에 대한 규제 승인에 기인할 수 있습니다.

원격 의료 솔루션의 성장은 향후 몇 년 동안 인간 호흡기 세포융합 바이러스 치료 시장의 확대를 촉진할 것으로 예측됩니다. 원격 의료는 통신 기술을 통해 원격 상담, 진단, 모니터링 및 치료가 가능한 디지털 헬스케어 서비스를 의미합니다. 원격 진료를 가능하게 해, 종래의 의료 시설의 부담을 경감하는 디지털 헬스케어 기술의 이용 확대에 의해 원격 의료 솔루션의 채택이 증가하고 있습니다. 가상 컨설팅을 지원하고 대면 통원의 필요성을 최소화하면서 환자 케어를 개선합니다. 이 기간의 텔레헬스 이용자는 약 2,188만 3,731명에 이르렀으며, 3분기부터 13% 증가했으며, 278만 3,159명의 이용자가 증가했습니다.

인간 호흡기 세포융합 바이러스 치료 시장의 주요 기업은 경쟁력을 유지하기 위해 단일클론항체 및 항바이러스제와 같은 혁신적인 치료법의 개발에 주력하고 있습니다. 단일 클론 항체는 신체가 감염과 싸우는 데 도움이 되는 실험실에서 만들어진 단백질이며, 항바이러스제는 바이러스의 증식이나 확산을 방지하도록 설계되어 있습니다. 그리고 고위험 소아에서 RSV 하기도 질환의 예방을 목적으로 한 단일클론항체 베이포르타스(닐세비맙 알립)의 미국 식품의약국(FDA) 승인을 발표했습니다. 이번 승인은 베이포르투스가 RSV 시즌 내내 수동 면역을 제공하는 지속적인 단일 용량 치료제를 제공함에 따라 RSV 예방에 큰 진전을 이루었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Human respiratory syncytial virus (RSV) treatment focuses on managing symptoms and preventing complications, especially in vulnerable populations. It typically involves supportive care to alleviate breathing difficulties, reduce fever, and ensure adequate hydration. In severe cases, hospitalization may be necessary for oxygen therapy and close monitoring. Prevention strategies are also essential in minimizing the risk of infection.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary treatment types for human respiratory syncytial virus are antiviral medications, monoclonal antibodies, vaccines, and supportive care. Antiviral medications are designed to treat viral infections by inhibiting virus replication, thereby reducing the severity and duration of illness and preventing complications. Treatment is administered to both pediatric and adult patients, with various routes of administration including oral and parenteral. These treatments are provided by several end-users, such as hospitals, clinics, and home care settings.

The human respiratory syncytial virus treatment market research report is one of a series of new reports from The Business Research Company that provides human respiratory syncytial virus treatment market statistics, including the human respiratory syncytial virus treatment industry global market size, regional shares, competitors with the human respiratory syncytial virus treatment market share, detailed human respiratory syncytial virus treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the human respiratory syncytial virus treatment industry. These human respiratory syncytial virus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human respiratory syncytial virus treatment market size has grown strongly in recent years. It will grow from$1.69 billion in 2024 to $1.84 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to rising RSV infection rates, an increase in the infant and elderly populations, a growth in hospital admissions due to respiratory illnesses, government vaccination programs, and heightened awareness of RSV complications.

The human respiratory syncytial virus treatment market size is expected to see strong growth in the next few years. It will grow to$2.58 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to the rising demand for monoclonal antibodies, increasing investment in RSV vaccine development, a growing focus on early diagnosis, expanding access to healthcare in developing regions, and regulatory approvals for new treatments. Key trends in the forecast period include the development of long-acting RSV antibodies, a focus on combination therapies, AI-driven drug discovery for RSV, the growing use of telemedicine for respiratory infections, and pharmaceutical collaborations for RSV drug development.

The growth of telehealth solutions is expected to drive the expansion of the human respiratory syncytial virus (RSV) treatment market in the coming years. Telehealth refers to digital healthcare services that allow for remote consultations, diagnosis, monitoring, and treatment through telecommunication technologies. The adoption of telehealth solutions is increasing, driven by the growing use of digital healthcare technologies, which enable remote care and ease the burden on traditional healthcare facilities. Telehealth for RSV treatment supports remote monitoring, early detection, and virtual consultations, improving patient care while minimizing the need for in-person hospital visits. For instance, according to Telehealth.HHS.gov, a US-based government information provider, telehealth usage in the fourth quarter of 2023 reached approximately 21,883,731 users, reflecting a 13% increase from the third quarter, with an additional 2,783,159 users. Thus, the rise of telehealth solutions is contributing to the growth of the RSV treatment market.

Leading companies in the human respiratory syncytial virus treatment market are focusing on developing innovative therapies, such as monoclonal antibodies and antiviral drugs, to maintain a competitive edge. Monoclonal antibodies are lab-engineered proteins that help the body combat infections, while antiviral drugs are designed to prevent viruses from multiplying or spreading. For example, in July 2023, AstraZeneca plc, a UK-based biopharmaceutical company, partnered with Sanofi S.A., a French pharmaceutical company, to announce the U.S. Food and Drug Administration (FDA) approval of Beyfortus (nirsevimab-alip), a monoclonal antibody aimed at preventing RSV lower respiratory tract disease in infants and high-risk children. This approval marked a significant advancement in RSV prevention, as Beyfortus offers a long-acting, single-dose treatment that provides passive immunity throughout the RSV season. It is particularly beneficial for newborns and infants, who are most vulnerable to severe RSV infections, reducing hospitalizations and complications.

In June 2022, Pfizer Inc., a US-based pharmaceutical company, acquired ReViral Ltd. for $525 million. This acquisition strengthens Pfizer's infectious disease portfolio and accelerates the development of innovative antiviral therapies for respiratory syncytial virus (RSV). ReViral Ltd., a UK-based company, specializes in developing treatments specifically for RSV.

Major players in the human respiratory syncytial virus treatment market are Pfizer Inc., Merck & Co, Sanofi S.A., AstraZeneca plc, GSK plc, Johnson & Johnson, Moderna Inc., Kyowa Kirin Co. Ltd., Novavax Inc., Alnylam Pharmaceuticals Inc., AdVaccine Biotechnology Co. Ltd., Enanta Pharmaceuticals Inc., Aridis Pharmaceuticals Inc., Synairgen plc, VBI Vaccines Inc., SAB Biotherapeutics Inc., Meissa Vaccines Inc., Osivax SAS, Codagenix Inc., and BioVaxys Technology Corp.

North America was the largest region in the human respiratory syncytial virus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human respiratory syncytial virus treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human respiratory syncytial virus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human respiratory syncytial virus treatment market consists of revenues earned by entities by providing services such as oxygen therapy, mechanical ventilation, hydration therapy, and fever and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The human respiratory syncytial virus treatment market also includes sales of medications, monoclonal antibodies, and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Respiratory Syncytial Virus Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human respiratory syncytial virus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for human respiratory syncytial virus treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human respiratory syncytial virus treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Human Respiratory Syncytial Virus Treatment Market Characteristics

3. Human Respiratory Syncytial Virus Treatment Market Trends And Strategies

4. Human Respiratory Syncytial Virus Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Respiratory Syncytial Virus Treatment Growth Analysis And Strategic Analysis Framework

6. Human Respiratory Syncytial Virus Treatment Market Segmentation

7. Human Respiratory Syncytial Virus Treatment Market Regional And Country Analysis

8. Asia-Pacific Human Respiratory Syncytial Virus Treatment Market

9. China Human Respiratory Syncytial Virus Treatment Market

10. India Human Respiratory Syncytial Virus Treatment Market

11. Japan Human Respiratory Syncytial Virus Treatment Market

12. Australia Human Respiratory Syncytial Virus Treatment Market

13. Indonesia Human Respiratory Syncytial Virus Treatment Market

14. South Korea Human Respiratory Syncytial Virus Treatment Market

15. Western Europe Human Respiratory Syncytial Virus Treatment Market

16. UK Human Respiratory Syncytial Virus Treatment Market

17. Germany Human Respiratory Syncytial Virus Treatment Market

18. France Human Respiratory Syncytial Virus Treatment Market

19. Italy Human Respiratory Syncytial Virus Treatment Market

20. Spain Human Respiratory Syncytial Virus Treatment Market

21. Eastern Europe Human Respiratory Syncytial Virus Treatment Market

22. Russia Human Respiratory Syncytial Virus Treatment Market

23. North America Human Respiratory Syncytial Virus Treatment Market

24. USA Human Respiratory Syncytial Virus Treatment Market

25. Canada Human Respiratory Syncytial Virus Treatment Market

26. South America Human Respiratory Syncytial Virus Treatment Market

27. Brazil Human Respiratory Syncytial Virus Treatment Market

28. Middle East Human Respiratory Syncytial Virus Treatment Market

29. Africa Human Respiratory Syncytial Virus Treatment Market

30. Human Respiratory Syncytial Virus Treatment Market Competitive Landscape And Company Profiles

31. Human Respiratory Syncytial Virus Treatment Market Other Major And Innovative Companies

32. Global Human Respiratory Syncytial Virus Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Respiratory Syncytial Virus Treatment Market

34. Recent Developments In The Human Respiratory Syncytial Virus Treatment Market

35. Human Respiratory Syncytial Virus Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기